NCT04181060

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2020-12-28Est. Completion: 2026-12-31

Enrollment target: 300 participants

Locations

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Anchorage Oncology Centre, Anchorage, Alaska, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States

Non-Small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegosto…

Anchorage, United StatesEst. completion Dec 28, 2029

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy i…

Gilbert, United StatesEst. completion Feb 13, 2032

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.